Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBIT (2017 - 2025)

Historic EBIT for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$17.1 million.

  • Aclaris Therapeutics' EBIT fell 6377.61% to -$17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.3 million, marking a year-over-year decrease of 23111.46%. This contributed to the annual value of -$141.9 million for FY2024, which is 4578.51% down from last year.
  • Aclaris Therapeutics' EBIT amounted to -$17.1 million in Q3 2025, which was down 6377.61% from -$18.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year EBIT high stood at -$4.0 million for Q4 2023, and its period low was -$99.7 million during Q4 2024.
  • Its 5-year average for EBIT is -$24.9 million, with a median of -$20.3 million in 2021.
  • Its EBIT has fluctuated over the past 5 years, first soared by 8608.27% in 2023, then crashed by 236293.55% in 2024.
  • Aclaris Therapeutics' EBIT (Quarter) stood at -$22.9 million in 2021, then dropped by 27.02% to -$29.1 million in 2022, then skyrocketed by 86.08% to -$4.0 million in 2023, then tumbled by 2362.94% to -$99.7 million in 2024, then surged by 82.8% to -$17.1 million in 2025.
  • Its last three reported values are -$17.1 million in Q3 2025, -$18.4 million for Q2 2025, and -$18.1 million during Q1 2025.